Stock Events

Stock Events

AbCellera Biologics 

€3.97
589
-€0.03-0.63% Today

Statistics

Day High
3.97
Day Low
3.97
52W High
5.81
52W Low
1.7
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q4 2025
Next
-0.15
-0.11
-0.07
-0.03
Expected EPS
-0.14629579431
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8QQ.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the discovery, development, and commercialization of treatments for serious medical conditions, similar to AbCellera's focus on antibody therapies.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies offers immune-driven medicine solutions, directly competing with AbCellera's antibody discovery for therapeutic use.
Novavax
NVAX
Mkt Cap1.32B
Novavax is involved in the development of vaccines and therapeutics, which overlaps with AbCellera's work on antibody therapies for infectious diseases.
Moderna
MRNA
Mkt Cap17.99B
Moderna is known for its mRNA technology but also competes in the broader biotech space, including therapeutic antibodies, similar to AbCellera.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech SE, while famous for its COVID-19 vaccine, also works on novel therapeutics, including antibodies, making it a competitor.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area of biotech that could compete with antibody-based therapies offered by AbCellera.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals focuses on creating new therapies for serious diseases, a mission that aligns with AbCellera's, making them competitors in the biotech space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could rival AbCellera's antibody-based treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotechnology giant with a broad portfolio that includes antibody therapeutics, making it a competitor across several of AbCellera's areas of interest.

About

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Carl L.G. Hansen Ph.D.
Employees
562
Country
Canada
ISIN
CA00288U1066

Listings

STU
DE
8QQ.STU
MU
DE
8QQ.MU
F
DE
8QQ.F
XNAS
US
ABCL

0 Comments

Share your thoughts

FAQ

What is AbCellera Biologics stock price today?▼
The current price of 8QQ.STU is €3.97 EUR — it has decreased by -0.63% in the past 24 hours. Watch AbCellera Biologics stock price performance more closely on the chart.
What is AbCellera Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AbCellera Biologics stocks are traded under the ticker 8QQ.STU.
Is AbCellera Biologics stock price growing?▼
8QQ.STU stock has risen by +20.88% compared to the previous week, the month change is a +30.77% rise, over the last year AbCellera Biologics has showed a +125.48% increase.
When is the next AbCellera Biologics earnings date?▼
AbCellera Biologics is going to release the next earnings report on May 11, 2026.
What were AbCellera Biologics earnings last quarter?▼
8QQ.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.11 EUR resulting in a +77.61% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does AbCellera Biologics have?▼
As of May 06, 2026, the company has 562 employees.
In which sector is AbCellera Biologics located?▼
AbCellera Biologics operates in the Health & Wellness sector.
When did AbCellera Biologics complete a stock split?▼
AbCellera Biologics has not had any recent stock splits.
Where is AbCellera Biologics headquartered?▼
AbCellera Biologics is headquartered in Vancouver, Canada.